Table 2.
Clinical and laboratory characteristics of the study sample at time of enrollment subdivided according to Apo CIII plasma concentration with the median value (10.3 mg/dL) as threshold level.
| Apo CIII < 10.3 mg/dL (n = 59) | Apo CIII ≥ 10.3 mg/dL (n = 59) | |
|---|---|---|
| Age (years) | 67 (60–76) | 69 (59–74) |
| Male gender (n, %) | 47, 79.66 | 32, 54.24 |
| BMI (kg/m2) | 27.16 (23.23–28.98) | 25.48 (23.19–30.15) |
| Coronary artery disease (n, %) | 29, 49.15 | 33, 55.93 |
| Previous stroke/TIA (n, %) | 4, 6.78 | 4, 6.78 |
| Congestive heart failure (n, %) | 6, 10.17 | 4, 6.78 |
| Atrial fibrillation (n, %) | 29, 49.15 | 33, 55.93 |
| Diabetes (n, %) | 8, 13.5 | 17, 28.81 |
| Hypertension (n, %) | 27, 45.76 | 39, 66.10 |
| Smoke habit (n, %) | 26, 44.07 | 32, 54.24 |
| CHA 2 DS 2 -VASc ( n , %) | ||
| 0 | 15, 25.42 | 3, 5.08 |
| 1 | 11,18.64 | 15, 25.42 |
| ≥2 | 33, 55.93 | 41, 69.49 |
| Laboratory parameters | ||
| Creatinine (μmol/L) | 92.40 (79.73–105.10) | 86.30 (76.44–104.25) |
| Total Cholesterol (mmol/L) | 4.47 (3.80–5.14) | 5.40 (4.43–6.33) |
| LDL Cholesterol (mmol/L) | 2.96 (2.34–3.62) | 3.59 (2.76–4.35) |
| HDL Cholesterol (mmol/L) | 1.20 (1.04–1.34) | 1.26 (1.04–1.59) |
| Triglyceride (mmol/L) | 1.13 (0.95–1.49) | 1.89 (1.46–2.37) |
| Apo AI (g/L) | 1.20 (1.02–1.42) | 1.42 (1.23–1.58) |
| Apo B (g/L) | 0.86 (0.71–1.04) | 1.09 (0.94–1.32) |
| Apo CIII (mg/dL) | 9.02 (7.92–9.68) | 12.30 (11.41–15.76) |
| Apo E (g/L) | 0.034 (0.029–0.040) | 0.039 (0.032–0.049) |
| Follow-up events | ||
| Ischemic Stroke/TIA (n, %) | 6, 10.17 | 18, 30.51 |
Distributions of continuous variables were expressed as median value with interquartile range (IQR). Categorical variables were expressed as proportions.